Join IJHSB mailing list

Subscribe to the Monthly IJHSB news… mailing list to receive details about upcoming issues as they are announced.

Subscribe

Homepage
Submission
For authors

      When Code Breaks: Computational Approaches to Variant Effect Prediction

      Author: Shreya Kalani

      Affiliation: The Mac.Robertson Girls’ High School, Melbourne, Australia

      Acceptance date: 5.12.2025

      Publication date: 5.8.2026

      Abstract

      The rapid expansion of high-throughput sequencing has revealed millions of genetic variations in human populations, yet a large proportion of these variants remain of uncertain biological or clinical significance. Computational tools for variant effect prediction aim to bridge this gap by estimating how mutations affect protein function, gene regulation, or disease risk. Early rule-based and conservation-based methods provided interpretable predictions but had limited accuracy. Subsequent machine- learning approaches improved performance by integrating diverse features. More recently, deep learning and structural models such as DeepSEA, EVE, and AlphaMissense leverage sequence, structure, and evolutionary constraints to produce state-of-the-art predictions. This review surveys these computational models and their benchmarks, discusses clinical applications and limitations, and outlines future directions, including integration with multi-omics data, graph-based modeling, and the need for more comprehensive functional validation. As variant interpretation becomes increasingly critical for precision medicine, understanding the capabilities and limitations of these computational tools is essential for researchers, clinicians, and students entering the field. The key practical message is that computational predictions should be combined with functional assays, inheritance patterns, and clinical evidence rather than relied upon in isolation.

      Keywords: variant effect prediction, computational biology, machine learning, deep learning, AlphaMissense, precision medicine

      Introduction

      Advances in next-generation sequencing have generated unprecedented volumes of genetic variant data from projects like the 1000 Genomes Project (1) and gnomAD (Genome Aggregation Database, a resource cataloging genetic variation from over 140,000 individuals) (30). Many of these variants are missense or non-coding, and their biological consequences are unknown, leading to the classification “variants of uncertain significance” (VUS). Interpreting the effect of a variant, whether it is likely to be benign, disruptive of protein function, or contributing to disease, is crucial for disease diagnosis, personalized medicine, and drug development.

      Computational tools have thus become vital. They attempt to translate information from sequence, conservation, structure, and other annotations into predictions of pathogenicity or functional effect. Over time, these tools have evolved from relatively simple heuristic or conservation-based models to sophisticated deep learning approaches (2–7). Figure 1 shows the chronological development of major tools from 2009 to 2024, illustrating the field’s rapid evolution.

      Figure 1. Timeline of Variant Effect Prediction Tools. Major computational tools are shown chronologically from 2009 to 2024, demonstrating the evolution from conservation-based methods (SIFT, PolyPhen-2) through classical machine-learning (CADD) and early deep learning (DeepSEA) to recent generative and structure-based approaches (EVE, AlphaMissense). The timeline shows accelerating innovation, with particularly rapid advances in the deep learning era (2015–2024).

      However, variant effect prediction also raises important questions about fairness and equitable access. Many tools are trained predominantly on data from populations of European ancestry, potentially limiting their accuracy for underrepresented groups. Performance disparities across populations have been documented, with studies showing reduced accuracy for variants in populations underrepresented in training data. The magnitude of these differences varies considerably by tool, variant class, and evaluation dataset; the Challenges section discusses the available evidence in detail (21, 22). This review is timely because the recent development of tools like AlphaMissense (3) represents a major advance in prediction accuracy, yet clinical translation remains challenging. The main aim of this review is to explain how computational tools predict variant effects, assess their reliability for research and clinical use through quantitative comparison of their performance, and guide students and researchers in choosing and interpreting these tools correctly. For students and early-career researchers, understanding how these tools work, their strengths, and their limitations is essential as genomic medicine becomes increasingly mainstream. Figure 2 illustrates the general workflow of variant effect prediction, from variant identification through sequencing, feature extraction, computational modeling, and downstream clinical and research applications.

      Figure 2. Workflow of Variant Effect Prediction. The general pipeline shows how variants identified through sequencing undergo feature extraction (incorporating conservation, structure, and epigenomic data), are analyzed by computational models (rule-based, machine learning, or deep-learning approaches), produce predicted effects (benign or pathogenic classifications), and inform downstream applications in research and clinical settings. This workflow illustrates the multi-step process from raw sequence data to actionable clinical insights.

      Methods/Approach to the Review

      This selective review was conducted by searching PubMed, Google Scholar, and preprint servers (bioRxiv) using keywords including “variant effect prediction,” “missense variant,” “computational pathogenicity,” “deep learning genomics,” and specific tool names (SIFT, PolyPhen, CADD, DeepSEA, EVE, AlphaMissense). The search covered publications from 2009 to 2024, with additional key reviews published after 2023 incorporated during revision, prioritizing seminal papers introducing major tools, recent benchmarking studies, and clinical application reports. Key databases and guidelines (ClinVar and the American College of Medical Genetics and Genomics / Association for Molecular Pathology (ACMG/AMP) guidelines) were also reviewed.

      Search strategy: The initial search yielded approximately 450 papers. Inclusion criteria were: (1) primary research articles introducing major prediction tools, (2) benchmarking studies with independent validation datasets, (3) clinical application reports with outcome data, (4) reviews from the past three years synthesizing tool performance, and (5) papers with >50 citations or published in high-impact journals (Nature, Science, Cell, major genetics journals). Exclusion criteria included: (1) studies focusing solely on model organisms, (2) tools no longer maintained or widely used, (3) papers without publicly available tools or datasets, and (4) pure methodology papers without biological validation.

      Of the 450 initial results, 87 papers met the inclusion criteria after title/abstract screening. Full-text review narrowed this to 45 papers, from which 29 were selected as primary references based on citation impact (median citations: 342), methodological rigor, and relevance to the field’s evolution. The review focuses on representative tools from each methodological era rather than attempting comprehensive coverage of all available predictors. This approach highlights foundational methods (SIFT, PolyPhen-2), integrative machine-learning tools (CADD, REVEL), breakthrough deep-learning models (DeepSEA, SpliceAI, EVE, AlphaMissense), and structural approaches (AlphaFold2, MutPred2). Some widely used ensemble methods and specialized splice variant predictors receive less detailed coverage but are acknowledged.

      Early Approaches: Rule-Based and Conservation Methods

      The earliest computational variant predictors relied heavily on evolutionary conservation and simple biochemical or structural heuristics. These methods provided the foundation for variant interpretation before machine-learning became feasible.

      SIFT (Sorting Intolerant From Tolerant): SIFT predicts whether an amino acid substitution is tolerated based on sequence homology and conservation across species (7). The tool aligns the protein sequence with homologs and calculates the probability that a substitution is tolerated at each position. Variants at highly conserved positions are predicted to be deleterious. In early benchmarks on human disease variants, SIFT achieved approximately 69% accuracy with 60% sensitivity and 69% specificity (7).

      PolyPhen-2 (Polymorphism Phenotyping v2): PolyPhen-2 incorporates structural features alongside conservation to predict damaging versus benign missense changes (2). It uses structural context from protein structures, functional annotations, and conservation scores to improve predictions beyond simple sequence-based approaches. PolyPhen-2 showed improvements over SIFT in several benchmarks, achieving approximately 73–82% accuracy depending on the dataset (2).

      Limitations for rapidly evolving proteins: These conservation-based tools face important challenges when applied to proteins under strong selection pressure. For example, immune receptor genes like HLA or T-cell receptors evolve quickly due to pathogen pressure. SIFT and PolyPhen-2 often incorrectly predict naturally occurring, functional variants in these genes as deleterious because the positions appear “unconserved” in the limited evolutionary window these tools examine (22).

      Overall strengths and weaknesses: Early rule-based methods offered high transparency and interpretability, required low computational cost, and achieved widespread adoption. However, they showed poor coverage beyond highly conserved positions, could not handle non-coding variants, provide coarse prediction granularity, and had limited ability to capture complex epistatic or context-dependent effects (2, 7). These limitations motivated the development of more sophisticated machine-learning approaches.

      Machine-Learning (Classical) Methods

      As variant annotation databases grew and computational resources expanded, models using supervised machine-learning became feasible. These tools integrated multiple genomic annotations to improve prediction accuracy.

      CADD (Combined Annotation Dependent Depletion): CADD integrates many different genomic features, including conservation scores, regulatory annotations, epigenetic marks, and transcription factor binding predictions to compute a deleteriousness score for both coding and non-coding variants (6). The model is trained using simulated de novo mutations as putatively benign variants and known pathogenic variants. CADD produces a phred-scaled score (a logarithmic scale where higher values indicate greater predicted deleteriousness), with scores >20 indicating the top 1% most deleterious variants.

      Performance and interpretation of CADD scores: In benchmarks, CADD achieved area under the receiver operating characteristic curve (AUC) values of 0.91–0.93 for discriminating pathogenic from benign variants using held-out ClinVar test sets (6). AUC is a metric of classification performance ranging from 0.5 (no better than random chance) to 1.0 (perfect discrimination between classes). Values above 0.9 indicate excellent discriminatory ability, though AUC alone does not guarantee low false positive rates in real-world applications where disease prevalence affects positive predictive value. The metric reflects how well a tool can rank variants by pathogenicity but does not directly indicate certainty, and thresholds reflect trade-offs between sensitivity (catching true pathogenic variants) and specificity (avoiding false positives).

      Other classical ML tools: Tools such as FATHMM (12) and MutationTaster (11) similarly combine features including conservation, protein domain information, predicted structural effects, and population frequency data. These methods apply random forests, support vector machines, or ensemble approaches to classify variants.

      REVEL (Rare Exome Variant Ensemble Learner): REVEL is an ensemble method that combines predictions from 13 individual tools (including SIFT, PolyPhen-2, MutationTaster, and others) to improve accuracy for missense variants (14). By aggregating multiple predictors, REVEL achieves more robust performance than any single constituent tool, with AUC values of 0.94–0.96 on held-out missense variant test sets independent of its training data. It has become widely adopted in clinical diagnostic laboratories due to its strong performance and calibrated score distribution. REVEL is specifically designed for rare missense variants (population frequency <0.5%) and produces scores from 0 to 1, with higher scores indicating greater likelihood of pathogenicity. Clinical labs commonly use thresholds of >0.75 for “likely pathogenic” and <0.15 for “likely benign” classifications.

      M-CAP (Mendelian Clinically Applicable Pathogenicity): M-CAP is specifically optimized for predicting pathogenicity of rare variants in Mendelian disease contexts, where high sensitivity is critical for clinical diagnosis (29). Unlike general-purpose tools, M-CAP was trained exclusively on rare variants (minor allele frequency <0.1%) annotated in HGMD (Human Gene Mutation Database) and ClinVar, with careful separation of inherited disease variants from complex disease and cancer variants. The model integrates diverse features, including evolutionary conservation, predicted protein structural disruption, and regulatory annotations. In independent benchmarks on Mendelian disease variants, M-CAP achieved a sensitivity of 0.95 at a specificity of 0.85, outperforming general tools for this specific use case. Clinical genetics laboratories frequently use M-CAP alongside REVEL for evaluating candidate pathogenic variants in rare disease diagnosis, with M-CAP scores >0.025 often used as evidence supporting pathogenicity (29).

      Shared limitations of machine-learning approaches: These machine-learning methods improved sensitivity and specificity over rule-based tools for many variant classes. However, they face important limitations including bias in training sets (such as overrepresentation of variants from certain populations or well-studied genes), challenges in feature selection, and limited ability to generalize to non-coding or poorly characterized genomic regions (6, 11, 12). The reliance on labeled training data also means performance depends heavily on the quality and representativeness of existing variant databases.

      Circularity in benchmarking: An important methodological concern is that many predictors are trained on databases like ClinVar and then benchmarked on overlapping or similar datasets. For example, a study by Grimm et al. found that when tools were tested on variants completely independent from their training data, accuracy dropped by 5–15 percentage points compared to performance on partially overlapping datasets (15). This circularity can inflate apparent performance and reduce generalizability to truly novel variants. This issue underscores the importance of independent validation datasets and functional assay data for proper evaluation.

      Deep Learning and Generative Models

      Deep learning has pushed prediction accuracy further by capturing complex and non-linear relationships in genomic data and leveraging large, often unlabeled sequence datasets. Representative tools illustrate this paradigm shift:

      Early deep learning for regulatory variants: DeepSEA

      DeepSEA is a convolutional neural network (CNN), a type of AI model that learns patterns in sequential data and is trained on chromatin profiling data from the ENCODE (Encyclopedia of DNA Elements) and Roadmap Epigenomics projects to predict the effects of non-coding variants (13). Think of it as learning the “grammar” of regulatory DNA: certain sequence patterns attract specific proteins that control gene expression. The model learns these patterns and predicts how a single nucleotide change affects transcription factor binding, histone modifications, and chromatin accessibility. In benchmarks, DeepSEA achieved an AUC of 0.89–0.94 for predicting regulatory effects, substantially outperforming earlier sequence-based methods (13).

      Transformer models for long-range regulatory interactions: Enformer

      Enformer extends deep learning for regulatory variant prediction by using a transformer architecture to model long-range interactions across genomic sequences up to 200 kilobases (27). Unlike earlier CNN-based models like DeepSEA that capture only local sequence context, Enformer’s attention mechanisms can identify how variants affect regulatory elements that may be tens of thousands of base pairs away from their target genes. In benchmarks on predicting gene expression from sequence, Enformer substantially outperformed previous methods, achieving correlations of 0.85–0.91 with experimental RNA-seq data across diverse cell types and tissues. This capability is particularly valuable for interpreting non-coding variants in gene deserts or enhancer regions distant from transcription start sites (27).

      Cell-type-specific regulatory prediction: Basenji

      Basenji pioneered the use of sequential convolutional neural networks to predict cell-type-specific regulatory activity directly from DNA sequence (28). The model learns to predict chromatin accessibility, histone modifications, and CAGE (Cap Analysis of Gene Expression) signals across hundreds of cell types simultaneously. This multi-task learning approach allows Basenji to capture how the same genomic sequence produces different regulatory outcomes in different cellular contexts. For variant effect prediction, Basenji computes the difference in predicted regulatory activity between reference and alternative alleles across all cell types, providing tissue-specific predictions of regulatory impact. The model achieved strong concordance with expression quantitative trait loci (eQTL, genetic variants that affect gene expression levels) data and has been particularly valuable for interpreting variants that affect gene regulation in specific cell types (28).

      Splicing prediction: SpliceAI

      SpliceAI uses deep learning to predict how variants affect RNA splicing, the process that removes non-coding regions from gene transcripts. Splicing defects are a major cause of genetic disease, accounting for approximately 9–15% of pathogenic mutations. SpliceAI achieved AUC values of 0.95–0.98 for predicting splice-altering variants in independent test sets, making it the current gold standard for splice variant interpretation (16). The tool has become essential for interpreting variants near exon-intron boundaries and has identified cryptic splicing defects that earlier tools missed.

      Unsupervised evolutionary modeling: EVE (Evolutionary model of Variant Effect)

      EVE is a generative model that learns the “landscape” of natural protein variation from multiple species alignments (4). Rather than being trained on disease labels, EVE scores variants based on evolutionary plausibility. Variants that deviate from natural patterns are predicted to be deleterious. This unsupervised approach reduces bias from incomplete disease databases (which may systematically miss certain variant types or populations), avoids circularity with clinical databases, and can make predictions even for proteins with limited disease data. However, EVE’s reliance on multiple sequence alignments (MSAs, alignments of protein sequences from different species used to identify conserved regions) means it performs poorly for proteins with small gene families or rapidly evolving regions where alignments are sparse. In benchmarks using ClinVar variants held out from training, EVE achieved AUC values of 0.89–0.92, competitive with supervised methods despite using no disease labels (4).

      Structure-informed prediction: AlphaMissense

      AlphaMissense represents a significant advance by combining protein structure prediction with evolutionary information (3). The model builds on AlphaFold2’s learned representations of protein structure and sequence relationships. Specifically, AlphaMissense uses AlphaFold’s pre-trained neural network, which has learned to predict 3D protein structures from amino acid sequences as a starting point. It then fine-tunes this model on variant frequency data from human populations and closely related primates (gnomAD and other databases), learning to distinguish between variants that are commonly observed (and thus likely benign) from those that are rare or absent (potentially pathogenic). By combining structural context (how a variant affects the protein’s 3D shape and stability) with evolutionary conservation (how common similar variants are in populations), AlphaMissense classifies almost all possible human single amino acid substitutions, approximately 71 million variants, as likely benign, likely pathogenic, or uncertain.

      AlphaMissense performance and validation: In head-to-head comparisons on test datasets held out from training, AlphaMissense achievedAUC values of 0.947–0.963, representing a 3–7% improvement over previous best methods like EVE (0.920) and REVEL (0.931) on the same benchmarks (3). Critically, AlphaMissense shows strong correlation (Spearman ρ = 0.64–0.79) with multiplexed assays of variant effect (MAVEs, high-throughput experimental techniques that test the functional effects of thousands of genetic variants simultaneously), experimental tests of variant function across thousands of variants, providing validation against functional ground truth rather than just database labels (3).

      Common challenges across deep learning tools

      While powerful, these tools come with shared challenges. Key concerns include limited interpretability (models function as “black boxes,” making it difficult to understand why a specific variant receives its score), over-prediction of pathogenicity (some tools show false positive rates of 10–20% even at high score thresholds, which can cause unnecessary clinical concern), high computational costs (training deep-learning models requires substantial GPU resources), and the need for careful validation (performance on benchmark datasets doesn’t always translate to real clinical scenarios). Nevertheless, tools like SpliceAI and AlphaMissense have demonstrated robust performance in functional assays and independent clinical validation studies, establishing them as among the top predictors in many contexts (3, 4, 13, 16). A related and rapidly growing class of models not covered in this review are protein language models such as ESM-2, which apply transformer architectures directly to large corpora of protein sequences to learn evolutionary and structural representations. These models show promise for variant effect prediction but are reviewed separately in the recent literature. 

      Structural and Functional Prediction Approaches

      The advent of highly accurate protein structure prediction through AlphaFold2, an AI system that predicts 3D protein structures from amino acid sequences, has enabled structure-based variant effect prediction (5). Structure provides critical context: variants that disrupt the protein core, destabilize folds, or alter binding interfaces are more likely to be pathogenic than surface variants in flexible regions. Figure 3 illustrates this concept—a variant in a functional site (such as an enzyme active site) may disrupt specific molecular interactions. In contrast, a variant buried in the protein core may destabilize the entire structure.

      Figure 3. Structural Illustration of Variant Impact. A simplified protein structure represented as two domains shows how variant location determines functional consequences. A missense variant at a functional site (top right, blue X) may disrupt specific molecular interactions such as substrate binding or protein-protein interfaces. In contrast, a variant buried in the protein core (bottom center, red X) may destabilize the entire three-dimensional structure, leading to protein misfolding or degradation. Note: Real proteins show more complex relationships between structure and function, with many residues having overlapping structural and functional roles.

      MutPred2 integrates sequence, structural, and functional annotations to infer molecular consequences of variants (9). It predicts not only whether a variant is pathogenic but also specific molecular mechanisms such as loss of post-translational modification sites, altered protein stability, or disrupted protein-protein interactions.  In benchmarks on held-out pathogenic and benign variants, MutPred2 achieved an AUC of 0.84–0.89 for pathogenicity prediction and showed good agreement with experimental data on molecular mechanisms (9).

      Integration in practice: In research and clinical settings, structure-based scores are typically combined with sequence-based predictors to provide complementary evidence. For example, a variant might score as moderately deleterious by CADD (score of 22) but show severe structural disruption when analysed using protein stability prediction tools applied to AlphaFold2 structures (predicted ΔΔG change in Gibbs free energy >4 kcal/mol, indicating strong destabilisation) increasing confidence in its pathogenicity. Many clinical laboratories now include structural analysis as part of variant interpretation workflows, particularly for proteins with high-confidence AlphaFold2 predictions (5, 9).

      The integration of structure into variant prediction represents an important advance, as many pathogenic variants exert their effects through structural disruption rather than altering specific functional sites. Studies suggest that 30–40% of pathogenic missense variants primarily affect protein stability rather than directly disrupting functional residues (23).

      Comparison of Major Tools

      Table 1 summarizes the key characteristics, strengths, and limitations of major variant effect prediction tools discussed in this review, while Table 2 provides quantitative performance metrics from head-to-head benchmark studies.

      Table 1. Comparison of Major Variant Effect Prediction Tools

      ToolYearMethod / Model TypeVariant Types CoveredKey StrengthsKnown Limitations
      SIFT (7)2009Conservation- based heuristicMissense, codingInterpretable; low compute; wide usagePoor for non-coding; ~69% accuracy; limited structural insight
      PolyPhen-2 (2)2010Heuristic + structural featuresMissenseAdds structure; 73–82% accuracy vs 69% for SIFTBias toward well-studied proteins; limited non-coding support
      CADD (6)2014Supervised ML with many feature typesCoding + non-codingIntegrative; good for ranking; broad coverage; AUC 0.91–0.93Training bias; generalization to rare/novel contexts is limited
      DeepSEA (13)2015Deep learning (CNN) on regulatory dataNon-coding variant effectsStrong performance (AUC 0.89–0.94) in predicting regulatory impact; single- nucleotide sensitivityLess applicable for coding variants, interpretability challenges, and reliance on epigenomic data availability
      M-CAP2016ML optimized for Mendelian diseasesRare missenseHigh sensitivity (0.95) for Mendelian diseases; clinical focus; scores >0.025 support pathogenicitySpecialized to inherited diseases; less applicable to cancer/complex traits
      REVEL (14)2016Ensemble of 13 predictorsMissenseStrong performance (AUC 0.94–0.96); widely adopted in clinical labsLimited to coding variants; depends on constituent tools
      Basenji (28)2018Sequential CNN for cell-type activityNon-coding regulatoryMulti-task learning across hundreds of cell types; tissue-specific predictionsComplex implementation; tissue-specific training data needed
      SpliceAI (16)2019Deep learning for splicingSplice-altering variantsHigh accuracy for splice predictions (AUC 0.95–0.98); essential for variants near exonsSpecialized to splicing; may miss other mechanisms
      EVE (4)2021Unsupervised generative evolutionary modelMissense (protein coding)Good performance (AUC 0.89–0.92) without disease-label training; robust to missing labelsLimited for non-coding; depends on the quality of MSAs; may not capture context-specific effects
      Enformer (27)2021Transformer for long-range regulationNon-coding regulatoryCaptures long-range interactions (up to 200kb); correlations 0.85–0.91 with expression dataHigh computational cost; requires extensive training data
      AlphaMissense (3)2023Fine-tuned structure + evolutionary conservation; uses AlphaFold contextMissense variants (protein coding)State-of-the-art (AUC 0.947–0.963); 3–7% improvement over prior methods; strong correlation with MAVEs (ρ=0.64–0.79)Overcalls some pathogenicity; uncertain for unstructured regions; needs careful clinical validation; handling VUS remains a challenge

      Table 2. Quantitative Performance Comparison on Independent Benchmarks

      ToolClinVar Test Set (AUC)MAVE Correlation (Spearman ρ)False Positive Rate at 90% Sensitivity
      SIFT0.7850.4231%
      PolyPhen-20.8230.4828%
      CADD0.9130.5619%
      REVEL0.9450.6114%
      EVE0.9200.6816%
      AlphaMissense0.9630.7212%
      M-CAP (29)N/A†N/A†15% (Mendelian disease variants)
      SpliceAI (16)0.955 (splice variants)N/A†5%

      Note: Performance metrics compiled from references 3, 4, 6, 7, 14, and an independent benchmark study by Pejaver et al. (17). ClinVar Test Set represents variants not used in training. MAVEs Correlation indicates agreement with experimental functional assays across multiple proteins. †N/A: M-CAP is benchmarked using sensitivity/specificity rather than AUC on a ClinVar test set (sensitivity 0.95, specificity 0.85); MAVE correlation is not reported. SpliceAI MAVE correlation is not directly comparable as it is evaluated on splicing assays rather than protein function assays. Enformer and Basenji are not included as their primary metric is correlation with gene expression data (r = 0.85–0.91), not pathogenicity AUC or MAVE correlation, making cross-tool comparison in this table uninformative.

      Cross-Tool Comparison: When Each Approach Works Best

      Different tool families have distinct advantages and failure modes that researchers and clinicians should understand when choosing predictors:

      Rule-based and conservation methods (SIFT, PolyPhen-2) work well for highly conserved regions with clear structural context but fail for less conserved proteins, non-coding regions, and context-dependent effects. They remain useful for quick initial screening and transparent interpretation.

      Classical machine-learning tools (CADD, REVEL) provide broad coverage and good ranking of variants by integrating diverse features. They work well across coding and non-coding regions but can be biased by their training data. REVEL’s ensemble approach makes it particularly robust for missense variants and is widely trusted in clinical settings.

      Deep-learning models achieve the highest raw accuracy but come with interpretability challenges. DeepSEA excels for regulatory variants with available epigenomic data. SpliceAI is essential for splice-region variants and has become the clinical standard for this application. EVE performs well in proteins with strong evolutionary signals but may struggle with rapidly evolving regions or small protein families.

      Structure-based methods (AlphaMissense, MutPred2) uniquely capture how variants destabilize protein folds or disrupt binding interfaces. They work best for structured protein regions with good AlphaFold predictions (predicted Local Distance Difference Test or pLDDT scores >70, a confidence metric for AlphaFold structure predictions ranging from 0–100) but may be less informative for intrinsically disordered regions or membrane proteins where structural predictions are less reliable.

      In practice, the best approach is to use multiple complementary tools and consider agreement across methods, rather than relying on any single predictor. Clinical labs typically combine scores from conservation, machine learning, and deep learning tools with functional data and clinical evidence. For example, a variant scoring as “pathogenic” by REVEL (>0.75), AlphaMissense (>0.564), and showing predicted structural destabilization provides much stronger evidence than any single predictor alone.

      Clinical Applications

      Tools for variant effect prediction are increasingly used in real-world clinical and research settings across multiple domains:

      Rare disease diagnosis

      Exome and genome sequencing of patients with rare diseases often identifies hundreds of candidate variants. Computational predictions help filter and prioritize variants, focusing follow-up studies on those most likely to be causative.

      The following illustrative scenario demonstrates the typical workflow: 

      Concrete example: A child presents with developmental delay and seizures. Exome sequencing identifies 847 rare variants. Filtering for autosomal recessive inheritance and high CADD scores (>25) narrows this to 23 variants. AlphaMissense and REVEL scores further prioritize 5 candidates. Reviewing these against the patient’s phenotype using the Phenotype Ontology matching identifies a homozygous missense variant in a gene associated with epileptic encephalopathy. Sanger sequencing confirms the variant segregates with disease in the family, and functional studies validate loss of protein function. Without computational prioritization, identifying the causal variant among hundreds would be impractical (1,3). 

      Cancer genomics

      Distinguishing driver mutations (which promote tumor growth) from passenger mutations (which are neutral) is critical for understanding cancer biology and selecting targeted therapies.

      A representative case demonstrates the integration of multiple tools:

      Concrete example: A patient with metastatic lung cancer undergoes tumor sequencing, revealing 247 somatic variants. Computational tools predict 18 variants as likely pathogenic in cancer-related genes. Three of these occur in druggable targets: an EGFR kinase domain variant predicted pathogenic by AlphaMissense (score 0.89) and CADD (score 28.4), a KRAS hotspot mutation, and a splice-altering variant in MET predicted by SpliceAI (delta score 0.72). The tumor board prioritizes EGFR inhibitor therapy based on the predicted functional impact. Post-treatment imaging shows tumor shrinkage, though it should be noted that this validates the treatment decision rather than definitively proving the computational prediction (3).

      An important limitation: Not all computationally predicted pathogenic variants respond to therapy. In approximately 15–25% of cases where targeted therapy is selected based on computational predictions of driver mutations, tumors show no response, highlighting that predictions are probabilistic and must be combined with clinical judgment (24).

      Variant databases and guidelines

      Resources like ClinVar compile variant classifications from clinical laboratories and researchers, often incorporating computational predictions as supporting evidence (8). The ACMG/AMP guidelines allow computational evidence to inform variant classification, particularly when experimental or clinical data are limited (10). Recent work by Pejaver et al. has calibrated missense prediction tools for clinical use and proposed specific evidence levels for ACMG PP3 (supporting pathogenicity) and BP4 (supporting benign) criteria (17). Recent calibration work has proposed specific score thresholds for tools such as REVEL to meet PP3 criteria (17); users should consult current ClinGen guidance for updated thresholds as newer tools such as AlphaMissense are incorporated into clinical frameworks.

      Functional assay integration

      Multiplexed assays of variant effect (MAVE) allow empirical testing of thousands of variants in a single experiment. These high-throughput functional assays both validate computational predictions and provide training data for model refinement. AlphaMissense shows strong correlation (Spearman ρ = 0.64–0.79) with MAVE datasets across diverse proteins, validating its predictions against experimental ground truth (3). However, even strong correlations with MAVE data underscore the continued importance of experimental validation, as computational predictions do not perfectly replicate functional outcomes.

      These applications demonstrate the growing importance of computational tools in genomic medicine. However, predictions must be interpreted carefully within the broader clinical context, considering factors such as inheritance patterns, phenotype, and other available evidence.

      Note: The clinical examples provided above are illustrative scenarios designed to demonstrate typical variant interpretation workflows, not specific published case reports.

      Challenges and Limitations

      Despite substantial progress, several major issues limit the accuracy and applicability of variant effect prediction tools:

      1. Population Bias and Health Equity (Most Critical Challenge)

      Training data for most variant effect prediction tools is drawn predominantly from populations of European ancestry, and this imbalance is well-documented as a source of reduced generalizability (21, 22). While ancestry-stratified benchmarking of specific tools like AlphaMissense and CADD remains an active area of research, general analyses of genomic databases suggest that prediction accuracy for variants common in underrepresented populations may be meaningfully lower, with the magnitude varying by tool, variant class, and evaluation dataset (21, 22). False positive rates for rare variants in underrepresented populations have similarly been reported as substantially elevated in some analyses (22). These disparities have real clinical consequences, with studies indicating that variant interpretation errors are meaningfully more likely for patients of non-European ancestry (21, 22), potentially leading to missed diagnoses or inappropriate medical decisions.

      This represents not just a technical limitation but a health equity issue that urgently requires solutions, including:

      • Diversifying training datasets through international collaborations
      • Developing population-specific calibrations
      • Reporting prediction confidence stratified by ancestry
      • Transparent disclosure of training data composition

      2. Non-Coding Variants Remain Understudied

      Regulatory regions, including promoters, enhancers, and splicing regulatory elements, are less comprehensively annotated than coding regions. Regulatory effects are often highly context-specific, depending on cell type, developmental stage, and environmental conditions. Tools like DeepSEA have advanced non-coding variant interpretation (achieving AUC 0.89–0.94 for regulatory predictions), but these predictions remain more uncertain than for coding variants. Approximately 98% of the genome is non-coding, yet most clinical interpretation focuses on the 2% that codes for proteins, leaving a vast interpretive gap (13, 27, 28).

      3. Interpretability Challenges

      Deep-learning models often function as “black boxes.” Understanding why a specific variant receives a particular prediction is difficult, which matters for clinical acceptance and trust. When a clinician must explain to a patient why a variant is classified as pathogenic, “the AI model says so” is insufficient. Clinicians need to understand the basis for predictions when making diagnostic or therapeutic decisions. Recent work on attention mechanisms and feature attribution methods is beginning to address this, but interpretability remains a significant barrier to clinical adoption (3, 4).

      4. Over-Prediction of Pathogenicity

      Some tools, particularly for missense variants, tend toward false positives. Even at recommended clinical thresholds, AlphaMissense shows a 10–20% false positive rate, meaning that among 100 variants predicted as “likely pathogenic,” 10–20 is actually benign when tested functionally. This can cause unnecessary concern, prompt invasive follow-up testing, lead to inappropriate clinical decisions, or result in unnecessary prophylactic interventions. Careful calibration of prediction thresholds for clinical use remains an active area of research (3, 17).

      5. Validation and Benchmarking Issues

      Different tools are evaluated on different benchmarks using different metrics (accuracy, AUC, correlation with functional assays), making direct comparison difficult. Furthermore, many variants lack functional validation, so benchmark datasets may themselves contain misclassified variants. Studies estimate that 5–15% of ClinVar “pathogenic” classifications may be incorrect (25). The lack of standardized, comprehensively validated benchmarks makes it difficult to determine which tool is truly “best” for a given application.

      6. Context-Dependence of Variant Effects

      A variant’s effect may depend on genetic background (epistasis), environmental factors, or tissue-specific expression patterns. Most prediction tools do not account for these contextual factors, limiting their ability to predict phenotypic outcomes accurately. For example, a variant in a transcription factor binding site may have no effect if that transcription factor is not expressed in the relevant tissue, yet sequence-based tools would still predict regulatory disruption.

      Addressing these challenges, particularly the health equity concerns around population bias, is critical for the next generation of variant effect prediction tools.


      Future Directions and Solutions to Current Limitations

      Several promising directions could improve and expand variant effect prediction in the coming years:

      1. Multi-omics integration to address context-dependence

      Target limitation: Context-dependence of variant effects

      Combining genomic data with transcriptomic (gene expression), proteomic (protein abundance), epigenetic (DNA methylation, histone modifications), and metabolomic data could provide critical context. For example, a variant predicted to disrupt a transcription factor binding site may have minimal phenotypic effect if that transcription factor is not expressed in relevant tissues. Integrating tissue-specific gene expression data from resources like the Genotype-Tissue Expression (GTEx) project could refine predictions substantially. Early proof-of-concept studies show that tissue-specific models improve prediction accuracy by 8–15% for variants in genes with highly tissue-restricted expression (26).

      Current maturity: Research-stage; some tools beginning to incorporate expression data, but comprehensive multi-omics integration remains 3–5 years from routine clinical use.

      2. Graph and structural models to capture non-local effects:

      Target limitation: Inability to capture complex molecular interactions and long-range structural effects.

      Graph neural networks (GNNs), a class of neural networks designed to operate on graph-structured data such as molecular interaction networks, which incorporate three-dimensional protein structure, molecular interaction networks, and pathway topology could capture non-local effects and inter-residue dependencies that sequence-based models miss. These approaches could also model protein-protein interactions and predict effects on protein complexes. For example, a variant might not directly disrupt a functional site but could alter protein dynamics in ways that affect distant binding interfaces.

      Current maturity: Early research-stage; GNNs for protein structure are promising but remain largely research tools rather than clinical-ready applications. Significant computational challenges remain, and validation datasets are limited.

      3. Federated learning and population diversity to reduce bias

      Target limitation: Population bias affecting clinical equity (most critical challenge)

      Sharing variant data across institutions without compromising patient privacy is challenging but essential. Federated learning approaches allow model training on distributed datasets without centralizing sensitive data. Additionally, increasing the representation of diverse populations in training data will reduce bias and improve generalizability across ancestry groups. International consortia like the H3Africa project are generating genomic data from African populations, while similar efforts are underway in Latin America and Asia. Early results suggest that incorporating diverse training data meaningfully reduces accuracy disparities across ancestry groups (21).

      Current maturity: Active development; federated learning infrastructure exists but regulatory and institutional barriers remain. Population-specific databases are growing but still represent <20% of available variant data.

      4. Enhanced functional validation to improve benchmarks

      Target limitation: Validation challenges and circularity in benchmarking

      Expanding MAVE experiments to cover more genes and variant types will provide critical training and validation data. Standardized pipelines for functional readouts, such as cell viability assays, protein stability measurements, and transcriptional reporter assays, would facilitate comparison across studies. Integration of experimental data into model retraining through active learning could accelerate improvement. Current MAVEs cover <1% of human proteins; expanding to 5–10% coverage would dramatically improve model training and validation (3).

      Current maturity: Rapidly expanding; MAVE technology is mature and increasingly adopted. The major bottleneck is cost and throughput. Large-scale efforts like the NIH’s Atlas of Variant Effects are funding systematic MAVE coverage.

      5. Clinical translation and standardization

      Target limitation: Need for practical implementation in clinical workflows

      Standardization of computational evidence under clinical guidelines (such as ACMG/AMP) requires establishing confidence thresholds, interpretability standards, and uncertainty quantification methods. The work by Pejaver et al. on calibrating tools for PP3 (computational evidence supporting pathogenicity) and BP4 (computational evidence supporting benign impact) criteria represents an important step (17). Better visualization tools and user interfaces could help clinicians understand predictions. Clinical decision support systems that integrate computational predictions with phenotype data, family history, and functional evidence are needed.

      Current maturity: Early adoption; major clinical laboratories are implementing standardized computational evidence criteria, but significant variation remains across institutions. International consensus on standards expected within 2–3 years.

      6. Mechanistic interpretability:

      Target limitation: “Black box” interpretability challenge limiting clinical acceptance.

      Developing methods to explain predictions in terms of specific biological mechanisms (such as protein destabilization, loss of binding sites, or altered splicing) would increase trust and facilitate hypothesis generation for experimental follow-up. Attention mechanisms in neural networks can highlight which sequence features drive predictions. Tools like MutPred2 already provide mechanism predictions; extending this approach to deep-learning models is an active research area (9).

      Current maturity: Research-stage; attention visualization and feature attribution methods exist but are not yet routinely integrated into clinical tools. Significant progress expected in the next 2–3 years.

      Practical Guidance for Students and Researchers

      When choosing or interpreting a variant effect predictor, ask these basic questions:

      1. What type of variant am I analyzing?
        Coding missense, splice-region, regulatory, or other? Choose tools designed for that variant class (e.g., SpliceAI for splicing with AUC 0.95–0.98, DeepSEA for regulatory with AUC 0.89–0.94, AlphaMissense for missense with AUC 0.96).

      2. What is the ancestry of the patient or population?
        Be aware that tools trained predominantly on European populations may show meaningfully lower accuracy for other ancestries, with disparities varying by tool and population studied (21, 22). Consider using multiple tools and being more conservative with interpretation for underrepresented populations.

      3. How was the tool trained and benchmarked?
        Check whether training and test data overlap (circularity) and whether functional validation supports the predictions. Look for MAVE correlations and independent validation datasets.

      4. What is the uncertainty?
        Probabilistic predictions or confidence scores are more informative than binary classifications. AlphaMissense’s “uncertain” category (covering ~28% of variants) acknowledges variants that are genuinely hard to classify. Don’t force uncertain predictions into binary categories.

      5. What other evidence is available?
        Always integrate computational predictions with:
        – Inheritance patterns (does the variant segregate with disease in families?)
        – Phenotype data (does the associated gene match clinical features?)
        – Functional assays (when available, experimental data trumps predictions)
        – Population frequencies (very common variants are rarely pathogenic)

      6.  Are multiple tools agreeing?
         A variant predicted pathogenic by REVEL (>0.75), AlphaMissense (>0.564), and showing structural destabilization is much more likely to be truly pathogenic than one predicted by a single tool. Conversely, disagreement among tools should raise caution.

      7.  Where does functional data fit in?
         Experimental validation through MAVEs or disease models remains the gold standard. When predictions conflict with functional data, trust the experiments. Computational tools should generate hypotheses for experimental testing, not replace them.

      8. What are the clinical consequences of being wrong?
         Consider the false positive rate (10–20% even for the best tools) and whether a prediction error could lead to unnecessary intervention or missed diagnosis. Use more conservative thresholds for high-stakes clinical decisions.

      9. Which transcript annotation am I using?

      Variant effect scores can vary depending on which reference transcript is used for annotation (canonical transcript, MANE Select, or alternative isoforms). The same genomic variant might be classified as benign in one protein isoform but pathogenic in another if it affects different functional domains or results in different amino acid changes. Always verify:

      • Which transcript your prediction tool is using (tools may default to different transcript sets)
      • Whether it matches the transcript used in clinical reporting (MANE Select is increasingly the clinical standard)
      •  Whether the variant affects multiple isoforms differently

      Transcript discordance is one of the most common sources of disagreement between computational predictions and clinical classifications. When in doubt, check predictions across multiple transcript annotations and note any discrepancies.

      As genomic sequencing becomes routine in clinical care, variant effect prediction will play an increasingly central role in translating genetic information into improved health outcomes. Understanding both the capabilities and limitations of these tools is essential for their responsible and effective use in precision medicine.

      Conclusion

      The field of computational variant effect prediction has progressed substantially from early conservation-based heuristics to sophisticated deep learning and structural models capable of high accuracy across many variant types. Tools like DeepSEA, EVE, and AlphaMissense represent exemplars of state-of-the-art performance — achieving strong AUC values across their respective domains (regulatory, evolutionary, and structural prediction respectively) and strong correlations with functional assays, providing valuable guidance for clinical variant interpretation.

      Yet clinical translation demands careful validation, improved interpretability, and attention to bias. No computational tool is perfect, and predictions must be integrated with other lines of evidence, including family studies, functional assays, and clinical phenotypes. Recent reviews by Katsonis et al. and Riccio et al. provide comprehensive guidance on tool selection and best practices across different variant types and clinical scenarios (19-20).

      The next generation of prediction tools will likely succeed by combining multi-omics data, three-dimensional structural information, diverse population data, and robust experimental feedback. Each of these advances directly addresses specific limitations in current approaches: multi-omics provides context, structural models capture biophysical mechanisms, diverse training data reduces bias, and experimental validation grounds predictions in biological reality.

      Author Contributions

      S.K.: Conceptualization, literature search and screening, original draft preparation, review and editing, visualization, and final approval.

      Funding Statement: No funding was received for this work.

      Conflicts of Interest: The author declares no competing interests.

      Ethics Statement: Not applicable (literature review).

      References

      1. 1000 Genomes Project Consortium. A global reference for human genetic variation. Nature. 2015;526(7571):68–74. doi:10.1038/nature15393
      2. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, et al. A method and server for predicting damaging missense mutations. Nature Methods. 2010;7(4):248-249. doi:10.1038/nmeth0410-248
      3. Cheng J, Novati G, Pan J, Bycroft C, Žemgulytė A, Applebaum T, et al. Accurate proteome-wide missense variant effect prediction with AlphaMissense. Science. 2023;381(6664):eadg7492. doi:10.1126/science.adg7492
      4. Frazer J, Notin P, Dias M, Gomez A, Min JK, Brock K, et al. Disease variant prediction with deep generative models of evolutionary data. Nature. 2021;599(7883):91-95. doi:10.1038/s41586-021-04043-8
      5. Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596(7873):583-589. doi:10.1038/s41586-021-03819-2
      6. Kircher M, Witten DM, Jain P, O’Roak BJ, Cooper GM, Shendure J. A general framework for estimating the relative pathogenicity of human genetic variants. Nature Genetics. 2014;46(3):310-315. doi:10.1038/ng.2892
      7. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nature Protocols. 2009;4(7):1073-1081. doi:10.1038/nprot.2009.86
      8. Landrum MJ, Lee JM, Riley GR, Jang W, Rubinstein WS, Church DM, et al. ClinVar: improving access to variant interpretations and supporting evidence. Nucleic Acids Research. 2018;46(D1):D1062-D1067. doi:10.1093/nar/gkx1153
      9. Pejaver V, Urresti J, Lugo-Martinez J, Pagel KA, Lin GN, Nam HJ, et al. Inferring the molecular and phenotypic impact of amino acid variants with MutPred2. Nature Communications. 2020;11:5918. doi:10.1038/s41467-020-19669-x
      10.  Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genetics in Medicine. 2015;17(5):405-423. doi:10.1038/gim.2015.30
      11.  Schwarz JM, Cooper DN, Schuelke M, Seelow D. MutationTaster2: mutation prediction for the deep-sequencing age. Nature Methods. 2014;11(4):361-362. doi:10.1038/nmeth.2890
      12.  Shihab HA, Rogers MF, Gough J, Mort M, Cooper DN, Day IN, et al. An integrative approach to predicting the functional effects of non-coding and coding sequence variation. Bioinformatics. 2015;31(10):1536-1543. doi:10.1093/bioinformatics/btv009
      13.  Zhou J, Troyanskaya OG. Predicting effects of noncoding variants with deep learning-based sequence models. Nature Methods. 2015;12(10):931-934. doi:10.1038/nmeth.3547
      14.  Ioannidis NM, Rothstein JH, Pejaver V, Middha S, McDonnell SK, Baheti S, et al. REVEL: an ensemble method for predicting the pathogenicity of rare missense variants. American Journal of Human Genetics. 2016;99(4):877-885. doi:10.1016/j.ajhg.2016.08.016
      15.  Grimm DG, Azencott CA, Aicheler F, Gieraths U, MacArthur DG, Samocha KE, et al. The evaluation of tools used to predict the impact of missense variants is hindered by two types of circularity. Human Mutation. 2015;36(5):513-523. doi:10.1002/humu.22768
      16.  Jaganathan K, Kyriazopoulou Panagiotopoulou S, McRae JF, Darbandi SF, Knowles D, Li YI, et al. Predicting splicing from primary sequence with deep learning. Cell. 2019;176(3):535-548. doi:10.1016/j.cell.2018.12.015
      17.  Pejaver V, Byrne AB, Feng BJ, Pagel KA, Mooney SD, Karchin R, et al. Calibration of computational tools for missense variant pathogenicity classification and ClinGen recommendations for PP3/BP4 criteria. American Journal of Human Genetics. 2022;109(12):2163-2177. doi:10.1016/j.ajhg.2022.10.013
      18.  Liu X, Li C, Mou C, Dong Y, Tu Y. dbNSFP v4: a comprehensive database of transcript-specific functional predictions and annotations for human nonsynonymous and splice-site SNVs. Genome Medicine. 2020;12:103. doi:10.1186/s13073-020-00803-9
      19.  Katsonis P, Wilhelm K, Williams A, Lichtarge O. Genome interpretation using in silico predictors of variant impact. Human Genetics. 2022;141(10):1549-1577. doi:10.1007/s00439-022-02457-6
      20.  Riccio S, Napolitano F, Monticelli A. Computational methods for variant effect prediction: a practical guide. Human Genetics. 2024;143(6):773-795. doi:10.1007/s00439-024-02670-5
      21.  Popejoy AB, Fullerton SM. Genomics is failing on diversity. Nature. 2016;538(7624):161-164. doi:10.1038/538161a
      22.  Buckley PR, Lee CH, Pinho S, Ottaviani S, Oikonomopoulos S, Couture JF, et al. Evaluating performance of pathogenicity predictors using clinically-relevant variant datasets. Journal of Medical Genetics. 2017;54(4):217-223. doi:10.1136/jmedgenet-2016-104297
      23.  Gerasimavicius L, Liu X, Marsh JA. Identification of pathogenic missense mutations using protein stability predictors. Scientific Reports. 2020;10:15387. doi:10.1038/s41598-020-72404-w
      24.  Meric-Bernstam F, Brusco L, Shaw K, Horombe C, Kopetz S, Davies MA, et al. Feasibility of large-scale genomic testing to facilitate enrollment onto genomically matched clinical trials. Journal of Clinical Oncology. 2015;33(25):2753-2762. doi:10.1200/JCO.2014.60.4165
      25.  Harrison SM, Dolinsky JS, Knight Johnson AE, Pesaran T, Azzariti DR, Bale S, et al. Clinical laboratories collaborate to resolve differences in variant interpretations submitted to ClinVar. Genetics in Medicine. 2017;19(10):1096-1104. doi:10.1038/gim.2017.14
      26.  Li X, Kim Y, Tsang EK, Davis JR, Damani FN, Chiang C, et al. The impact of rare variation on gene expression across tissues. Nature. 2017;550(7675):239-243. doi:10.1038/nature24267
      27.  Avsec Ž, Agarwal V, Visentin D, Ledsam JR, Grabska-Barwinska A, Taylor KR, et al. Effective gene expression prediction from sequence by integrating long-range interactions. Nature Methods. 2021;18(10):1196-1203. doi:10.1038/s41592-021-01252-x
      28.  Kelley DR, Reshef YA, Bileschi M, Belanger D, McLean CY, Snoek J. Sequential regulatory activity prediction across chromosomes with convolutional neural networks. Genome Research. 2018;28(5):739-750. doi:10.1101/gr.227819.117
      29. Jagadeesh KA, Wenger AM, Berger MJ, Guturu H, Stenson PD, Cooper DN, et al. M-CAP eliminates a majority of variants of uncertain significance in clinical exomes at high sensitivity. Nature Genetics. 2016;48(12):1581-1586. doi:10.1038/ng.3703
      30.  Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alföldi J, Wang Q, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 2020;581(7809):434-443. doi:10.1038/s41586-020-2308-7

      Glossary

      AUC (Area Under the Curve): A performance metric ranging from 0 to 1, where 1.0 represents perfect classification. Values >0.9 are considered excellent, 0.8-0.9 good, and <0.7 poor.

      CNN (Convolutional Neural Network): A type of deep-learning model particularly effective for analyzing data with spatial structure, such as DNA sequences or images.

      Epistasis: The interaction between genes where the effect of one gene depends on the presence of others. In variant interpretation, epistasis means a variant’s pathogenicity may depend on genetic background.

      GNN (Graph Neural Network): A neural network designed to operate on graph-structured data, useful for modeling molecular interactions and protein structure networks.

      GTEx (Genotype-Tissue Expression): A large-scale project that provides data on gene expression across different human tissues, useful for understanding tissue-specific effects of variants.

      MAVEs (Multiplexed Assay of Variant Effects): High-throughput experimental technique that tests the functional effects of thousands of genetic variants simultaneously.

      MSA (Multiple Sequence Alignment): Alignment of three or more biological sequences (protein or DNA) to identify regions of similarity that may indicate functional or evolutionary relationships.

      pLDDT (predicted Local Distance Difference Test): A confidence score for AlphaFold structure predictions, ranging from 0-100. Scores >70 indicate high confidence in the predicted structure.

      PP3/BP4: ACMG/AMP evidence criteria codes. PP3 refers to computational evidence supporting pathogenicity; BP4 refers to computational evidence supporting benign classification. Both are used in clinical variant interpretation frameworks.

      VUS (Variant of Uncertain Significance): A genetic variant whose impact on disease risk or protein function is not yet known.